How should I evaluate and treat overt and subclinical hypothyroidism and hyperthyroidism, including in pregnancy, and what are the recommended monitoring guidelines?

Thyroid Management: Evaluation and Treatment of Hypothyroidism and Hyperthyroidism

Evaluation of Suspected Thyroid Dysfunction

Measure TSH as the first-line screening test for thyroid dysfunction, as it demonstrates approximately 98% sensitivity and 92% specificity for detecting thyroid disease. 1

Initial Testing Algorithm

• For suspected hypothyroidism: Check TSH first; if elevated, measure free T4 to distinguish subclinical hypothyroidism (normal free T4) from overt hypothyroidism (low free T4) 1
• For suspected hyperthyroidism: Check TSH first; if suppressed (<0.1 mIU/L), measure free T4 and free T3 to distinguish subclinical from overt hyperthyroidism 2, 3
• Confirm all abnormal results with repeat testing after 3–6 weeks, as 30–60% of mildly abnormal TSH values normalize spontaneously 1

When to Measure Additional Tests

• Anti-TPO antibodies: Measure when TSH is elevated to identify autoimmune thyroiditis (Hashimoto's), which predicts higher progression risk to overt hypothyroidism (4.3% vs 2.6% annually in antibody-negative patients) 1
• Free T3: Measure only when TSH is suppressed but free T4 is normal, to identify T3 toxicosis 4, 5
• Thyroid scan with radioactive iodine uptake: Obtain when TSH <0.45 mIU/L to distinguish Graves' disease or toxic nodular goiter from destructive thyroiditis 2

---

Treatment of Overt Hypothyroidism

Initiate levothyroxine immediately when TSH is elevated AND free T4 is below the reference range, as untreated overt hypothyroidism causes cardiac dysfunction, adverse lipid profiles, and impaired quality of life. 1

Levothyroxine Dosing Strategy

• For patients <70 years without cardiac disease: Start at full replacement dose of approximately 1.6 mcg/kg/day 1
• For patients >70 years OR with cardiac disease/multiple comorbidities: Start at 25–50 mcg/day and increase by 12.5–25 mcg every 6–8 weeks 1
• Target TSH: 0.5–4.5 mIU/L with normal free T4 1

Critical Safety Precaution

Before initiating levothyroxine, measure morning cortisol and ACTH to exclude adrenal insufficiency, as starting thyroid hormone before adequate corticosteroid coverage can precipitate life-threatening adrenal crisis. 1 If adrenal insufficiency is confirmed, start hydrocortisone (20 mg morning, 10 mg afternoon) at least one week before levothyroxine 1

Monitoring Protocol

• During dose titration: Recheck TSH and free T4 every 6–8 weeks until target TSH is achieved 1
• Once stable: Monitor TSH every 6–12 months, or sooner if symptoms change 1
• Free T4 can help interpret ongoing abnormal TSH levels during therapy, as TSH may take longer to normalize 1

---

Treatment of Subclinical Hypothyroidism

TSH >10 mIU/L with Normal Free T4

Initiate levothyroxine therapy regardless of symptoms, as this TSH level carries approximately 5% annual risk of progression to overt hypothyroidism and is associated with cardiac dysfunction and adverse lipid profiles. 1 Evidence quality is rated as "fair" by expert panels 1

TSH 4.5–10 mIU/L with Normal Free T4

Routine levothyroxine treatment is NOT recommended for asymptomatic patients, as randomized controlled trials found no symptomatic benefit. 1 Instead, monitor TSH every 6–12 months 1

Consider treatment in specific situations:

• Symptomatic patients with fatigue, weight gain, cold intolerance, or constipation—offer a 3–4 month trial with clear evaluation of benefit 1
• Pregnant women or those planning pregnancy—treat any TSH elevation, targeting TSH <2.5 mIU/L in first trimester 1, 6
• Positive anti-TPO antibodies—higher progression risk (4.3% vs 2.6% annually) supports treatment consideration 1
• Patients with goiter or infertility 1

Risks of Overtreatment

Approximately 25% of patients on levothyroxine are unintentionally maintained on doses that fully suppress TSH, increasing risks for atrial fibrillation (3–5 fold), osteoporosis, fractures, and cardiovascular mortality, especially in patients >60 years. 1

---

Management of Subclinical Hyperthyroidism

TSH 0.1–0.45 mIU/L (Not on Levothyroxine)

Repeat TSH measurement along with free T4 and free T3 within 3 months to confirm persistence. 2 For patients with atrial fibrillation, cardiac disease, or serious medical conditions, repeat testing within 2 weeks 2

• If TSH remains 0.1–0.45 mIU/L with normal free T4 and T3: Retest at 3–12 month intervals until TSH normalizes or condition is stable 2
• Routine treatment is NOT recommended for all patients in this range 2
• Consider treatment if age >60, cardiac disease, osteoporosis risk, or symptomatic 1

TSH <0.1 mIU/L (Not on Levothyroxine)

Repeat TSH, free T4, and free T3 within 4 weeks (or sooner if cardiac symptoms present). 2 Obtain radioactive iodine uptake and scan to distinguish Graves' disease or toxic nodular goiter from destructive thyroiditis 2

Treatment is recommended for most patients with persistently suppressed TSH <0.1 mIU/L, especially if age >60, cardiac disease, or osteoporosis risk, due to increased risks of atrial fibrillation, bone loss, and cardiovascular mortality. 2, 1

Exogenous Subclinical Hyperthyroidism (On Levothyroxine)

When TSH is suppressed in a levothyroxine-treated patient, first review the indication for thyroid hormone therapy:

• For thyroid cancer patients: Consult treating endocrinologist to confirm target TSH level, as intentional suppression may be required (target varies by risk: 0.5–2 mIU/L for low-risk, 0.1–0.5 mIU/L for intermediate-risk, <0.1 mIU/L for structural incomplete response) 1
• For hypothyroidism without cancer/nodules: Reduce levothyroxine dose immediately 2, 1

Dose reduction strategy:

• If TSH <0.1 mIU/L: Decrease levothyroxine by 25–50 mcg 1
• If TSH 0.1–0.45 mIU/L: Decrease by 12.5–25 mcg, especially in elderly or cardiac patients 1

Prolonged TSH suppression increases risk for atrial fibrillation (especially in elderly), bone demineralization and fractures (especially in postmenopausal women), and potential cardiovascular mortality. 2, 1

---

Treatment of Overt Hyperthyroidism

Non-Pregnancy

Methimazole is the drug of choice for treating hyperthyroidism in non-pregnant patients. 7 Propylthiouracil should be avoided outside of first trimester pregnancy due to serious hepatotoxicity 7

Hyperthyroidism based on thyroid nodules and Graves' disease not achieving long-term remission require definitive treatment with surgery or radioiodine. 7 Radioiodine can be administered outpatient when radiation protection requirements are met 7

Pregnancy-Specific Management

Use propylthiouracil (PTU) exclusively during the first trimester, then switch to methimazole for the second and third trimesters to minimize both congenital malformations and maternal hepatotoxicity. 6

Treatment goals:

• Maintain free T4 or free thyroxine index in the high-normal range using the lowest possible thioamide dose 6
• Check free T4 or FTI every 2–4 weeks to adjust medication 6
• Once stable, check TSH every trimester 6

Monitor for agranulocytosis: If sore throat and fever develop, obtain complete blood count immediately and discontinue thioamide 6

Beta-blockers (e.g., propranolol) can temporarily manage symptoms like tremors and palpitations until thioamide therapy reduces thyroid hormone levels 6

Thyroid storm is a medical emergency requiring immediate treatment with PTU or methimazole, potassium/sodium iodide solutions, dexamethasone, phenobarbital, and supportive care without waiting for laboratory confirmation 6

Radioactive iodine (I-131) is absolutely contraindicated during pregnancy as it causes fetal thyroid ablation 6 Women must wait four months after I-131 treatment before breastfeeding 6

Untreated or inadequately treated hyperthyroidism increases risks of severe preeclampsia, preterm delivery, heart failure, miscarriage, and low birth weight. 6

---

Thyroid Management in Pregnancy

Hypothyroidism in Pregnancy

Treat all pregnant women with elevated TSH using levothyroxine to restore TSH to trimester-specific reference ranges, as untreated hypothyroidism increases risks of preeclampsia, low birth weight, and neuropsychological defects in offspring. 6

Dosing adjustments:

• Women with pre-existing hypothyroidism: Increase levothyroxine dose by 25–50% immediately upon pregnancy confirmation 1
• Target TSH <2.5 mIU/L in first trimester 1, 6
• Monitor TSH every 4 weeks until stable, then at minimum once per trimester 1

Postpartum Considerations

Inform the newborn's physician about maternal thyroid disease (both hyperthyroidism and hypothyroidism) due to risk of neonatal thyroid dysfunction 6

Women treated with PTU or methimazole can safely breastfeed 6

Monitor for postpartum thyroiditis in women with history of thyroid dysfunction 6

---

Common Pitfalls to Avoid

• Never treat based on a single abnormal TSH value—confirm with repeat testing, as 30–60% normalize spontaneously 1
• Never start thyroid hormone before ruling out adrenal insufficiency in suspected central hypothyroidism, as this can precipitate adrenal crisis 1
• Never use radioactive iodine during pregnancy—it causes fetal thyroid ablation 6
• Failing to switch from PTU to methimazole after first trimester increases risk of maternal hepatotoxicity 6
• Adjusting levothyroxine doses too frequently before reaching steady state (wait 6–8 weeks between adjustments) 1
• Overlooking non-thyroidal causes of TSH suppression—acute illness, medications, or recent iodine exposure can transiently affect TSH 1
• Underestimating fracture risk in elderly patients with TSH suppression—even slight overdose carries significant osteoporosis risk 1